Ciro Marangoni

Ciro Marangoni

Auto-generated profile, based on publicly available information

Ciro Marangoni

Centro Lucio Bini, Rome, Italy

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2016 in Journal of Affective Disorders
Verified
Journal Article
Closed access
CMCiro Marangoni
Ciro Marangoni
MHMariely Hernandez
Mariely Hernandez
GFGianni L. Faedda
Gianni L. Faedda

1 May 2013 in Journal of Affective Disorders
Verified
Journal Article
Closed access
RBRoss Baldessarini
Ross Baldessarini
GFGianni L. Faedda
Gianni L. Faedda
EOEmanuela Offidani
Emanuela Offidani
GVGustavo H. Vázquez
Gustavo H. Vázquez
CMCiro Marangoni
Ciro Marangoni
LTLeonardo Tondo
Leonardo Tondo

28 February 2017 in CNS Spectrums
Verified
Journal Article
Open access
PDF file
SSStephen Stahl
Stephen Stahl
DMDebbi A. Morrissette
Debbi A. Morrissette
GFGianni Faedda
Gianni Faedda
MFMaurizio Fava
Maurizio Fava
JGJoseph F. Goldberg
Joseph F. Goldberg
RMRoger S. McIntyre
Roger S. McIntyre
A significant minority of people presenting with a major depressive episode (MDE) experience co-occurring subsyndromal hypo/manic symptoms. As this presentation may have important prognostic and treatment implications, the DSM–5 codified a new nosological entity, the “mixed features specifier,” referring to individuals meeting threshold criteria for an MDE and subthreshold symptoms of (hypo)mania or to individuals with syndromal mania and subthreshold depressive symptoms. The mixed features specifier adds to a growing list of monikers that have been put forward to describe phenotypes characterized by the admixture of depressive and hypomanic symptoms (e.g., mixed depression, depression with mixed features, or depressive mixed states [DMX]). Current treatment guidelines, regulatory approvals, as well the current evidentiary base provide insufficient decision support to practitioners who provide care to individuals presenting with an MDE with mixed features. In addition, all existing psychotropic agents evaluated in mixed patients have largely been confined to patient populations meeting the DSM–IV definition of “mixed states” wherein the co-occurrence of threshold-level mania and threshold-level MDE was required. Toward the aim of assisting clinicians providing care to adults with MDE and mixed features, we have assembled a panel of experts on mood disorders to develop these guidelines on the recognition and treatment of mixed depression, based on the few studies that have focused specifically on DMX as well as decades of cumulated clinical experience.

1 October 2014 in Journal of Affective Disorders
Verified
Journal Article
Closed access
GFGianni L. Faedda
Gianni L. Faedda
GSGiulia Serra
Giulia Serra
CMCiro Marangoni
Ciro Marangoni
PSPaola Salvatore
Paola Salvatore
GSGabriele Sani
Gabriele Sani
AKAthanasios Koukopoulos
Athanasios Koukopoulos

27 May 2015 in The Journal of Clinical Psychiatry
Verified
Journal Article
Closed access
PDF file
GFGianni L. Faedda
Gianni L. Faedda
CMCiro Marangoni
Ciro Marangoni
GSGiulia Serra
Giulia Serra
PSPaola Salvatore
Paola Salvatore
GSGabriele Sani
Gabriele Sani
AKAthanasios Koukopoulos
Athanasios Koukopoulos
To evaluate the presence of affective signs and symptoms as precursors of bipolar disorder in prospective studies, including assessment of their prevalence, duration, and predictive value. We followed PRISMA guidelines to search PubMed, CINAHL, PsycINFO, EMBASE, SCOPUS, and ISI Web of Science databases to May 31, 2013, using the terms bipolar disorder AND (antecedent* OR predict* OR prodrom* OR prospect*) AND (diagnosis OR development). Hand searching of identified reports led to additional relevant references. We included only English-language articles containing (1) prospective, longitudinal studies with at least 2 structured clinical assessments (intake and follow-up); (2) no previous DSM-III or DSM-IV diagnoses of bipolar I or bipolar II; and (3) diagnostic outcome of bipolar I or bipolar II. Studies of subjects at familial risk of bipolar disorder were excluded, as these have been reviewed elsewhere. We tabulated details of study design, outcomes, precursors, and predictive value. Only studies reporting a positive predictive association were included. In 26 published reports meeting selection criteria, methods varied widely in terms of design, duration of follow-up, ages, and populations investigated. Despite such heterogeneity in methods, findings were notably consistent. Precursors of bipolar disorder include mood lability, subsyndromal and major depression, subsyndromal hypomanic symptoms with or without major depression, cyclothymia and bipolar not otherwise specified, major depression with psychotic features, and other psychotic disorders. Bipolar disorder was also predicted by juvenile onset of major depression as well as frequency and loading of hypomanic or depressive symptoms. Despite the limitations of published reports, prospectively identified precursors of bipolar disorder typically arose years prior to syndromal onset, often with significant early morbidity and disability. Prospectively identified precursors of bipolar disorder are generally consistent with findings in retrospective and family-risk studies. Combining precursors and other risk factors may increase predictive value, support earlier diagnosis, improve treatment, and limit disability in bipolar disorder.

19 June 2015 in Current Psychiatry Reports
Verified
Journal Article
Closed access
PDF file
CMCiro Marangoni
Ciro Marangoni
LCLavinia De Chiara
Lavinia De Chiara
GFGianni L. Faedda
Gianni L. Faedda